TR201111143T1 - NEW PHARMACEUTICAL CHOLINE PHENOFIBRATE COMPOSITIONS - Google Patents
NEW PHARMACEUTICAL CHOLINE PHENOFIBRATE COMPOSITIONSInfo
- Publication number
- TR201111143T1 TR201111143T1 TR2011/11143T TR201111143T TR201111143T1 TR 201111143 T1 TR201111143 T1 TR 201111143T1 TR 2011/11143 T TR2011/11143 T TR 2011/11143T TR 201111143 T TR201111143 T TR 201111143T TR 201111143 T1 TR201111143 T1 TR 201111143T1
- Authority
- TR
- Turkey
- Prior art keywords
- choline
- release
- pharmaceutical
- choline fenofibrate
- phenofibrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Salımı kontrollü farmasötik kolin fenofibrat bileşim(ler)i; bu bileşimler, kolin fenofibrat ve çeşitli yardımcı maddeler içeren bir merkez ve ayrıca, hızı kontrol eden ajan veya ajanlar içeren bir kaplama tabakasından meydana gelmektedir. Salımı kontrollü farmasötik kolin fenofibrat bileşim(ler)i, bu bileşimler, kolin fenofibrat ve bir veya daha fazla farmasötik yardımcı malzeme içeren suda çözünen inert madde içeren ve hemen salım sağlayan bir merkez ve aynca, hızı kontrol eden hidrofobik ajan veya ajanlar içeren bir kaplama tabakasından meydana gelir. Salımı kontrollü farmasötik kolin fenofibrat bileşim(ler)i; bu bileşimler, kolin fenofibrat ve bir veya daha fazla farmasötik yardımcı malzeme içeren suda çözünen inert madde içeren ve hemen salım sağlayan bir mericez ve aynca, hızı kontrol eden hidrofobik ajan veya ajanlar içeren bir kaplama tabakasından meydana gelir ve biyolojik olarak piyasada bulunan kolin fenofibrat (Trilipix®) formülasyonlarına eşdeğerdirler.Release controlled pharmaceutical choline fenofibrate composition (s); these compositions comprise a core comprising choline fenofibrate and various excipients as well as a coating layer comprising the rate controlling agent or agents. The release-controlled pharmaceutical choline fenofibrate composition (s) comprises a coating layer comprising a center which provides immediate release and also a rate-controlling hydrophobic agent or agents comprising choline fenofibrate and one or more pharmaceutical excipients, and an immediate release. it occurs. Release controlled pharmaceutical choline fenofibrate composition (s); these compositions comprise a release layer containing water-soluble inert materials containing choline fenofibrate and one or more pharmaceutical excipients, as well as immediate release, and a coating layer containing rate-controlling hydrophobic agent or agents, and the bioavailable choline phenofibrate (Trilipix). ®) formulations.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN724KO2009 | 2009-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201111143T1 true TR201111143T1 (en) | 2012-05-21 |
Family
ID=42732802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2011/11143T TR201111143T1 (en) | 2009-05-11 | 2010-05-10 | NEW PHARMACEUTICAL CHOLINE PHENOFIBRATE COMPOSITIONS |
Country Status (2)
Country | Link |
---|---|
TR (1) | TR201111143T1 (en) |
WO (1) | WO2010131265A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104473909A (en) * | 2014-11-21 | 2015-04-01 | 哈尔滨圣吉药业股份有限公司 | Choline fenofibric acid sustained release pellets and preparation method thereof |
CN105748445A (en) * | 2016-03-31 | 2016-07-13 | 武汉药谷生物工程有限公司 | Preparation method of choline fenofibrate acid sustained release capsule |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7276249B2 (en) * | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US20080051411A1 (en) * | 2002-12-17 | 2008-02-28 | Cink Russell D | Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof |
EP1868587A2 (en) * | 2005-04-08 | 2007-12-26 | Abbott Laboratories | Pharmaceutical formulations comprising fenofibric acid and/or its salts |
US20080152714A1 (en) * | 2005-04-08 | 2008-06-26 | Yi Gao | Pharmaceutical Formulations |
WO2009057138A2 (en) * | 2007-10-29 | 2009-05-07 | Lupin Limited | Controlled release pharmaceutical compositions of tolterodine |
-
2010
- 2010-05-10 WO PCT/IN2010/000298 patent/WO2010131265A1/en active Application Filing
- 2010-05-10 TR TR2011/11143T patent/TR201111143T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2010131265A1 (en) | 2010-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0913587A2 (en) | Composition, pesticidal agent, method for controlling phytopathogenic harmful funds, seed, use of one compound and another compound, and, composition. | |
ZA200809864B (en) | Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic | |
WO2009137391A3 (en) | Benzene sulfonamide thiazole and oxazole compounds | |
WO2010047765A8 (en) | Nanostructures for drug delivery | |
WO2012103038A3 (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
WO2012027065A3 (en) | Combination therapy for treatment of disease | |
BRPI0806531A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, THERAPEUTIC AGENT, AND USE OF THE COMPOUND. | |
SI1906939T1 (en) | Use of a partially neutralized, anionic (meth)acrylate copolymer as a coating for the production of a medicament releasing active substance at reduced ph values | |
EP3207946A3 (en) | Compositions comprising honey and a super-absorbent material | |
ES2556585T3 (en) | Compositions comprising salbutamol sulfate | |
MX350380B (en) | Zero-order modified release solid dosage forms. | |
GB0508110D0 (en) | Gene delivery | |
UA104866C2 (en) | Ocreotide implant having a release agent | |
BR112013015796A2 (en) | imaging agent composition, method of preparing an imaging agent composition, method of preparing an 18f-note chelator, and, pharmaceutical composition. | |
MX338413B (en) | Tooth film formulations. | |
WO2010027676A3 (en) | Dental composition comprising biphenyl di(meth)acrylate monomer | |
CL2007001838A1 (en) | COMPOUNDS DERIVED FROM 4-OXOQUINOLINE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND FOR THE PRODUCTION OF AN ANTI-HIV AGENT. | |
CL2007003356A1 (en) | COMPOUNDS DERIVED FROM BENZOPIRAZOLES; PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND ANOTHER ACTIVE AGENT; AND ITS USE FOR THE TREATMENT OF ASTHMA, INFLAMMATION, AMONG OTHER DISEASES. | |
EP3849404A4 (en) | Small highly uniform nanomedicine compositions for therapeutic, imaging and theranostic applications | |
BR112012025066A2 (en) | fluidizing mixture for hydraulic composition | |
MX2007013327A (en) | Extended release formulations. | |
WO2006060542A3 (en) | Formulations of substituted benzoxazoles | |
JP2008541745A5 (en) | ||
MX2010008852A (en) | Formulations of flibanserin. | |
PE20100471A1 (en) | SILDENAFIL PULSATILE RELEASE COMPOSITION AND PROCESS TO PREPARE IT |